137
Views
20
CrossRef citations to date
0
Altmetric
Review

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Pages 31-41 | Published online: 27 Sep 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Ashwani Sharma, Tarun Virmani, Anjali Sharma, Vaishnavi Chhabra, Girish Kumar, Kamla Pathak & Abdulsalam Alhalmi. (2022) Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity 15, pages 1845-1864.
Read now
Maria Lee & Mary K Rhee. (2015) Sitagliptin for Type 2 diabetes: a 2015 update. Expert Review of Cardiovascular Therapy 13:6, pages 597-610.
Read now
Jong-Ha Baek, Sang-Man Jin, Kohei Kaku, Jin-Ah Jung, Jung-Ryul Kim, Jae-Wook Ko, Min-Ji Kim, Soo-Youn Lee, Woo-seong Huh & Jae Hyeon Kim. (2015) Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment. Expert Opinion on Pharmacotherapy 16:8, pages 1127-1136.
Read now
Bo Ahrén. (2013) Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. European Diabetes Nursing 10:1, pages 31-36.
Read now

Articles from other publishers (15)

Xiao-Li Huang, Yang He, Li-Li Ji, Kai-Yu Wang, Yi-Li Wang, De-Fang Chen, Yi Geng, Ping OuYang & Wei-Min Lai. (2017) Hepatoprotective potential of isoquercitrin against type 2 diabetes-induced hepatic injury in rats. Oncotarget 8:60, pages 101545-101559.
Crossref
Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai & Hiroshi Itoh. (2015) C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Diabetes Research and Clinical Practice 108:3, pages 441-447.
Crossref
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Tomio Onuma, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto, Kazunari Matsumoto, Hiroki Yokoyama, Mamiko Tsugawa, Masahiko Gosho, Iichiro Shimomura & Hirotaka Watada. (2014) Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). Diabetology & Metabolic Syndrome 6:1.
Crossref
Regin Elsa George & Siby Joseph. (2014) A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal 22:5, pages 403-410.
Crossref
M. Alba, B. Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman & B. J. Goldstein. (2013) Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes, Obesity and Metabolism 15:12, pages 1101-1110.
Crossref
Maciej Sałaga, Marta Sobczak & Jakub Fichna. (2013) Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. Drug Discovery Today 18:15-16, pages 708-715.
Crossref
Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands & David Powell. (2013) Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics 35:3, pages 273-285.e7.
Crossref
Ebru Uçaktürk. (2013) Development of a gas chromatography–mass spectrometry method for the analysis of sitagliptin in human urine. Journal of Pharmaceutical and Biomedical Analysis 74, pages 71-76.
Crossref
Chih-Yuan Wang, Ching-Ling Lin, Tien-Shiang Huang, Ming-Nan Chien, Sheng-Hwu Hsieh, Yu-Yao Huang, Kuang-Chung Shih, Shih-Te Tu, Chwen-Tzuei Chang, Huang Chien-Ning, Chien-Wen Chou, Ta-Jen Wu, Rue-Tsuan Liu, Hing-Chung Lam, Ching-Fai Kwok, Chen-Chung Fu & Wayne H.-H. Sheu. (2012) Inertia on hypoglycemia: Highlight from a Taiwan subgroup analysis of Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Research and Clinical Practice 98:1, pages 61-67.
Crossref
C. F. Deacon, E. Mannucci & B. Ahrén. (2012) Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes, Obesity and Metabolism 14:8, pages 762-767.
Crossref
Pablo Aschner, Juliana Chan, David R Owens, Sylvie Picard, Edward Wang, Marie-Paule Dain, Valérie Pilorget, Akram Echtay & Vivian Fonseca. (2012) Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. The Lancet 379:9833, pages 2262-2269.
Crossref
S-I. Harashima, M. Ogura, D. Tanaka, T. Fukushima, Y. Wang, T. Koizumi, M. Aono, Y. Murata, M. Seike & N. Inagaki. (2012) Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. International Journal of Clinical Practice 66:5, pages 465-476.
Crossref
Bo Ahrén. (2012) DPP-4 inhibition and islet function. Journal of Diabetes Investigation 3:1, pages 3-10.
Crossref
Bo Ahrén. (2011) GLP-1 for type 2 diabetes. Experimental Cell Research 317:9, pages 1239-1245.
Crossref
Aviva Levina & Peter A. Lay. (2011) Metal-based anti-diabetic drugs: advances and challenges. Dalton Transactions 40:44, pages 11675.
Crossref